- Home
- ADIL vs PPBT Comparison
ADIL vs PPBT Comparison
Compare ADIL & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- PPBT
- Stock Information
- Founded
- ADIL 2010
- PPBT 2010
- Country
- ADIL United States
- PPBT Israel
- Employees
- ADIL N/A
- PPBT N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- PPBT Health Care
- Exchange
- ADIL Nasdaq
- PPBT Nasdaq
- Market Cap
- ADIL 6.0M
- PPBT 6.2M
- IPO Year
- ADIL 2018
- PPBT N/A
- Fundamental
- Price
- ADIL $0.38
- PPBT $1.42
- Analyst Decision
- ADIL Strong Buy
- PPBT Strong Buy
- Analyst Count
- ADIL 1
- PPBT 1
- Target Price
- ADIL $8.00
- PPBT $33.00
- AVG Volume (30 Days)
- ADIL 696.7K
- PPBT 34.9K
- Earning Date
- ADIL 08-13-2025
- PPBT 08-06-2025
- Dividend Yield
- ADIL N/A
- PPBT N/A
- EPS Growth
- ADIL N/A
- PPBT N/A
- EPS
- ADIL N/A
- PPBT N/A
- Revenue
- ADIL N/A
- PPBT N/A
- Revenue This Year
- ADIL N/A
- PPBT N/A
- Revenue Next Year
- ADIL N/A
- PPBT N/A
- P/E Ratio
- ADIL N/A
- PPBT N/A
- Revenue Growth
- ADIL N/A
- PPBT N/A
- 52 Week Low
- ADIL $0.22
- PPBT $1.40
- 52 Week High
- ADIL $1.30
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- ADIL 43.92
- PPBT 19.81
- Support Level
- ADIL $0.37
- PPBT $2.17
- Resistance Level
- ADIL $0.40
- PPBT $2.36
- Average True Range (ATR)
- ADIL 0.02
- PPBT 0.19
- MACD
- ADIL 0.00
- PPBT -0.05
- Stochastic Oscillator
- ADIL 27.83
- PPBT 2.00
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.